BioVAD
Accuracy of atrial fibrillation detection by an insertable cardiac monitor in patients undergoing catheter ablation: Results of the BioVAD study
Assaf A et al., Ann Noninvasive Electrocardiol., 2022
Study Design
- Prospective, observational, single-center study
- To evaluate the AF detection performance of BIOMONITOR III in patients before and after AF ablation
- 31 patients scheduled for catheter ablation of paroxysmal or persistent AF
Key Result 1
All true AF episodes were detected by the BIOMONITOR III
- 100% episode-based sensitivity
The BIOMONITOR III identified all patients with AF
- 100% patient-based sensitivity
BIOMONITOR III provided highly accurate AF burden estimation before and after catheter ablation
- 99.6% duration-based accuracy before catheter ablation
- 99.8% duration-based accuracy after catheter ablation
Key Result 2
78% reduction in false-positive episodes with RhythmCheck, the new ectopy rejection algorithm designed to minimize false positive AF detections due to ectopy
Clinical Relevance
- Insertable cardiac monitors (ICMs) are increasingly used to evaluate the atrial fibrillation (AF) burden after catheter ablation of AF
- Continuous monitoring provides the opportunity to establish the AF burden, which may have a better correlation with functional outcome than mere documentation of AF recurrence by intermittent rhythm monitoring strategies
- BIOMONIROR III accurately detects AF burden in patients before and after catheter ablation of AF
Study Objective |
|
---|---|
Primary Endpoint |
|
Clinical Sites |
|
Sample Size |
|
Main Inclusion Criteria |
|
Main Exclusion Criteria |
|
Principal Investigators |
|